Journal of International Oncology››2017,Vol. 44››Issue (7): 534-536.doi:10.3760/cma.j.issn.1673-422X.2017.07.014
Previous ArticlesNext Articles
Chen Lili, Lan Kuixu
Received:
2017-04-14Online:
2017-07-08Published:
2017-06-20Contact:
Chen Lili E-mail:qd_zhang_ning@163.comChen Lili, Lan Kuixu. RNA related markers of thyroid cancer[J]. Journal of International Oncology, 2017, 44(7): 534-536.
[1] Kim WB. A closer look at papillary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2015, 30(1): 1-6. DOI: 10.3803/EnM.2015.30.1.1. [2] Bisof V, Rakusic Z, Despot M. Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?[J]. Eur Arch Otorhinolaryngol, 2015, 272(7): 1553-1567. DOI: 10.1007/s00405-014-3108-1. [3] Sung JY, Na DG, Kim KS, et al. Diagnostic accueacy of fineneedle aspiration versus coreneedle biopsy for the diagnosis of thyroid malignancy in a clinical cohort[J]. Eur Radiol, 2012, 22(7): 15641572. DOI: 10.1007/s0033001224056. [4] Renshaw AA. Significance of repeatedly nondiagnostic thyroid fineneedle aspirations[J]. Am J Clin Pathol, 2011, 135(5): 750-752. DOI: 10.1309/AJCP8FX5CLPISSSK. [5] Anderson TJ, Atalay MK, Grand DJ, et al. Management of nodules with initially nondiagnostic results of thyroid fineneedle aspiration: can we avoid repeat biopsy?[J]. Radiology, 2014, 272(3): 777-784. DOI: 10.1148/radiol.14132134. [6] Yang F, Yi F, Zheng Z, et al. Charactreization of a carcinogenesisassociated long noncoding RNA[J]. RNA Biol, 2012, 9(1): 110-116. DOI: 10.4161/rna.9.1.18332. [7] Vriens MR, Weng J, Suh I, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer[J]. Cancer, 2012, 118(13): 3426-3432. DOI: 10.1002/cncr.26587. [8] Keutgen XM, Filicori F, Crowley MJ, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration[J]. Clin Cancer Res, 2012, 18(7): 2032-2038. DOI: 10.1158/1078-0432.CCR-11-2487. [9] Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation[J]. Eur J Endocrinol,2013, 168(5): 675-681. DOI: 10.1530/EJE-12-1029. [10] Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genomewide microRNA profiling in human and mouse tissues[J]. Proc Natl Acad Sci USA, 2014, 101(26): 9740-9744. DOI: 10.1073/pnas.0403293101. [11] Dettmer M, Vogetseder A, Durso MB, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas[J]. J Clin Endocrinol Metab, 2013, 98(1): E1-E7. DOI: 10.1210/jc.2012-2694. [12] Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2012, 97(6): 2084-2092. DOI: 10.1210/jc.2011-3059. [13] Moran VA, Perera RJ, Khalil AM, et al. Emerging functional and mechanistic paradigms of mammalian long noncoding RNAs[J]. Nucleic Acids Res, 2012, 40(14): 6391-6400. DOI: 10.1093/nar/gks296. [14] Wang Y, Guo Q, Zhao Y, et al. BRAFactivated long noncoding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma[J]. Oncol Lett, 2014, 8(5): 1947-1952. DOI: 10.3892/ol.2014.2487. [15] Rogounovitch TI, Bychkov A, Takahashi M, et al. The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population[J]. Thyroid, 2015, 25(3): 333-340. DOI: 10.1089/thy.2014.0431. [16] 翁侠, 洪晓明. LincRNAPVT1在甲状腺癌组织中的表达及意义[J].实用肿瘤杂志, 2017, 32(1): 57-61. DOI: 10.13267/j.cnki.syzlzz.2017.01.014. [17] Johnsson P, Morris KV. Expanding the functional role of long noncoding RNAs[J]. Cell Res, 2014, 24(11): 1284-1285. DOI: 10.1038/cr.2014.104. [18] Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression[J]. Ann Surg Oncol, 2014, 21(7): 2318-2325. DOI: 10.1245/s10434-014-3552-6. [19] Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a majr indicator of poor outcome in differentiated thyroid carcinomas[J]. J Clin Endocrinol Metab, 2014, 99(5): E754-E765. DOI: 10.1210/jc.2013-3734. [20] Patel MR, Stadler ME, Deal AM, et al. STT3A, C1orf24, TFF3: putative markers forcharacterization of follicular thyroid neoplasms from fineneedle aspirates[J]. Laryngoscope, 2011, 121(5): 983-989. DOI: 10.1002/lary.21736. [21] Im S, Yoo C, Jung JH, et al. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis[J]. Int J Med Sci, 2013, 10(2): 133140. DOI: 10.7150/ijms.5500. [22] Bernstein HG, Dobrowolny H, Trübner K, et al. Differential regional and cellular distribution of TFF3 peptide in the human brain[J]. Amino Acids, 2015, 47(5): 1053-1063. DOI: 10.1007/s00726-015-1938-9. [23] 王维健, 政峰. TFF3和半乳糖凝集素3在甲状腺肿瘤鉴别诊断中的临床意义[J]. 同济大学学报: 医学版, 2016, 37(6): 115-119. DOI: 10.16118/j.1008-0392.2016.06.023. [24] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29. DOI: 10.3322/caac.20138. [25] Jin L, Lloyd RV, Henry MR, et al. The diagnostic utility of combination of HMGA2 and IMP3 qRTPCR testing in thyroid neoplasms[J]. Appl Immunohistochem Mol Morphol, 2015, 23(1): 36-43. DOI: 10.1097/PAI.0000000000000031. |
[1] | Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190. |
[2] | Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway[J]. Journal of International Oncology, 2023, 50(7): 398-406. |
[3] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[4] | Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198. |
[5] | Jin Jiahui, Chen Cunhai, Ma Xuezhen.Effects of radiation-associated miRNA in radiotherapy for breast cancer[J]. Journal of International Oncology, 2022, 49(12): 735-738. |
[6] | Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei.Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 681-686. |
[7] | Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong.Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma[J]. Journal of International Oncology, 2022, 49(10): 581-585. |
[8] | Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50. |
[9] | Hong Anlan, Cao Meng, Wang Yan, Fang Fang.Research progress on lncRNAs as members of ceRNA network in melanoma[J]. Journal of International Oncology, 2022, 49(1): 61-64. |
[10] | Wu Yuping, Zhang Xiaoyu, Lu Keyi.Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment[J]. Journal of International Oncology, 2021, 48(9): 560-563. |
[11] | Feng Zhiping, Yang Chuanzhou, Chen Ting, Zhu Jialun, Liu Chao, Lyu Juan, Lu Jianmei, Deng Zhiyong.BRD4 inhibitor specifically inhibits the development of wild-type Kras differentiated thyroid carcinoma by regulating BRD4/miR-106b-5p/P21 axis[J]. Journal of International Oncology, 2021, 48(8): 463-472. |
[12] | Liu Pei, Pu Jiaze, Huang Wen, Wang Fei.Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis[J]. Journal of International Oncology, 2021, 48(7): 409-414. |
[13] | Wang Yang, Liu Qian, Long Hui, Wu Qingming.Research status of fecal detection for colorectal cancer markers[J]. Journal of International Oncology, 2021, 48(7): 441-444. |
[14] | Cheng Yiming, Li Gang, Wang Zhenming, Lyu Qianwen, Li Shirong.Value of serum miR-196a-5p and miR-105-5p in differential diagnosis of benign and malignant pulmonary nodules[J]. Journal of International Oncology, 2021, 48(5): 282-286. |
[15] | Deng Bo'er, Kong Weimin.Epigenetic research progress of endometrial cancer[J]. Journal of International Oncology, 2021, 48(3): 184-188. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||